Skip to main content
  • Teva Worldwide
  • About Teva Show Submenu
    • Our Company Profile
    • Facts & Figures
    • Our History
    • Our Values
    • Quality & Manufacturing
    • Our Code of Conduct

    Our mission is to be a global leader in generics and biopharmaceuticals, improving the lives of patients around the globe. For more than a century healthcare providers, patients, and caregivers have been using Teva’s medicines.

  • News & Media Show Submenu
    • Latest Teva News
    • Feature Stories
    • Media Inquiries
    • Media Kit

    Take a closer look at what we’re doing across Teva worldwide. View the latest press releases, feature stories, and company resources.

  • Products Show Submenu
    • Product Catalog
    • Generic Medicines
    • Specialty Medicines
    • Biopharmaceuticals
    • Report Adverse Effects
    • Patient Resources
    • Trade Partner Information

    At Teva we believe that every one of us should have access to quality medicine that helps manage disease, fight infection, or simply improves overall health. Around 200 million people worldwide take one of our medicines every day.

  • Our Impact Show Submenu
    • Our Commitment
    • Access to Medicine
    • ESG Progress Report
    • Economic Impact Report
    • Multiple Chronic Conditions
    • Patient Advocacy
    • Relationship with HCPs
    • Compliance

    Our commitment to making healthcare more accessible is steadfast. We recognize our responsibility and see it as an opportunity to improve lives and to make a lasting social impact.

  • Your Career Show Submenu
    • Why Join Teva
    • Working at Teva
    • Recruiting Process
    • Our People

    Teva is a place where great ideas flourish. We believe in empowering employees, presenting them with new challenges and enabling them grow and develop professionally, with a chance to make a real difference in people's lives.

  • Your Health
Teva USA
USA

Search Results

Showing 10 from 500 results

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Guidance at 8 a.m. ET on February 10, 2021

Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

Teva Reports Third Quarter 2020 Financial Results

Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY® (fremanezumab-vfrm) Injection Published in Headache

Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) Tablets in the U.S.

Teva to Host Conference Call to Discuss Third Quarter 2020 Financial Results at 8 a.m. ET on November 5, 2020

  • Previous
  • 1
  • …
  • 1
  • 1
  • 2
  • …
  • 50
  • Next page
  • Contact Us
  • Privacy Notice
  • Legal Notice
  • Teva Pharmacovigilance Privacy Policy
  • Teva Careers
  • Teva Worldwide
  • TAPI
Follow Teva
  • Facebook
  • Twitter
  • Linkedin